Presentation
Precision Pediatric Neurocritical Care: Genetic Diagnoses and Quantitative EEG for Tailored Therapies"
DescriptionIn the rapidly evolving field of pediatric neurocritical care, the integration of genetic diagnoses and quantitative EEG (qEEG) is paving the way for precision medicine. We will explore the latest advancements using case vignettes to highlight how rapid or known genetic testing allows for a more accurate diagnosis and prognosis and tailored therapies contributing to improved outcomes. Concurrently, we will examine how qEEG can be used to both monitor and measure cerebral function but also identify trends in seizure responsiveness that otherwise are difficult to identify.
Our discussion will begin with an examination of gain-of-function sodium channelopathies (SCN2A & SCN8A), which are some of the most common cause of early genetic epilepsies and can be targeted with sodium channel drugs. Cases presented will highlight how early diagnosis can improve seizure control with aggressive dosing regimens targeting high or "supra" therapeutic levels.
Next, the session will cover the role of qEEG in monitoring the efficacy of seizure therapies. Attendees will learn how real-time brain activity data can inform adjustments to treatment plans, ensuring that each child receives the most effective therapy based on their unique neurophysiological responses.
Finally, we will delve into the prognostic value of qEEG following cardiac arrest in children. New data continues strengthen the link between qEEG features (e.g., suppression ratio, and relative beta, alpha and delta activity) and the likelihood of neurological recovery. These features many help families make informed decisions about care and allow bedside providers to trend novel neuroprotective biomarkers.
Our discussion will begin with an examination of gain-of-function sodium channelopathies (SCN2A & SCN8A), which are some of the most common cause of early genetic epilepsies and can be targeted with sodium channel drugs. Cases presented will highlight how early diagnosis can improve seizure control with aggressive dosing regimens targeting high or "supra" therapeutic levels.
Next, the session will cover the role of qEEG in monitoring the efficacy of seizure therapies. Attendees will learn how real-time brain activity data can inform adjustments to treatment plans, ensuring that each child receives the most effective therapy based on their unique neurophysiological responses.
Finally, we will delve into the prognostic value of qEEG following cardiac arrest in children. New data continues strengthen the link between qEEG features (e.g., suppression ratio, and relative beta, alpha and delta activity) and the likelihood of neurological recovery. These features many help families make informed decisions about care and allow bedside providers to trend novel neuroprotective biomarkers.
Speaker
Associate Professor, Medical Director Inpatient Neuroscience UnitEvent Type
Breakout Session
TimeTuesday, October 15th3:05pm - 3:25pm PDT
LocationHarbor Ballroom A
Clinical Practice
Coma
Multimodal Neuromonitoring (invasive/non-invasive)
Pediatric
Provider Education Topics (eg fellowship training, competency assessment, etc)
Status Epilepticus
Intermediate